Both topical and systemic therapies are used in patients with cutaneous lupus erythematosus. According to one expert, the antimalarials are still the safest and often effective treatment approach. However, newer therapies may offer some hope in those especially challenging to treat recalcitrant cases of CLE.
Ilya Petrou, M.D.
The results of a recent population-based study confirms that the incidence of Cutaneous lupus erythematosus is not two to three times higher than the incidence of the more severe systemic lupus erythematosus form of the autoimmune disease, as anecdotally once thought.
Recent research demonstrates the central role that signaling pathways have in achieving normal adult hair follicle cycling.
The modulation of hair follicle components through the activation of ATP and cAMP can positively impact the structures in hair follicles.
Several noninvasive therapeutic approaches can be used to treat superficial basal cell carcinoma.
Automated robotic-assisted harvesting of follicular units can significantly reduce procedure time and costs of hair transplant surgery.
A recent study shows that nodal nevi do occur in the setting of Spitz nevi.
Antiphospholipid antibody syndrome: Autoimmune diseases, medications possible causes of purpura fulminans
Meningococcal infection is a common cause of purpura fulminans, followed by anticoagulant use, malignancy and connective tissue disease. After ruling out these etiologies, suspect autoimmune diseases and/or the medications used to treat these diseases as a possible cause of purpura fulminans secondary to antiphospholipid syndrome, an expert says.
Post-transplant lymphoproliferative disorder is lymphocyte proliferation in patients following post-transplant immunosuppression and is the most common neoplasm in pediatric organ transplant recipients. Due to the increased frequency of organ transplantation, dermatologists should be aware of the cutaneous presentation, as a timely diagnosis and treatment is crucial for a favorable prognosis.
Ingenol mebutate is a novel approach for the treatment of actinic keratoses. This new topical approach successfully treats AKs in only two or three days, — a much shorter therapeutic regimen compared to the current readily used topical approaches, such as solaraze, 5-FU and imiquimod, and, therefore, also increases patient compliance.